Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Presents Unprecedented Data Using Flow Electroporation for CHO-Based Transient Gene Expression to Achieve Gram Scale Antibody Production and Rapid Stable Cell Line Generation
May 20, 2013
Transient Gene Expression (TGE) Method Reporting Over 1 Gram/Liter Antibody Titersto be Presented at IBCs 9th Annual Cell Line Development & Engineering Conference
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting a series of events at IBCs 9th Annual Cell Line Development & Engineering Conference being held May 20-22 in La Jolla, CA. During this cutting-edge conference on innovations for bioproduct development, MaxCyte will present breakthrough transient gene expression (TGE) data in a scientific podium presentation and detail unmatched novel antibody production capabilities in two technical posters. MaxCyte scientists will be available throughout the conference at Booth #12 to provide technical details on the use of flow electroporation for large scale transient gene expression and rapid stable cell line generation.
Dr. James Brady, Director of Technical Applications at MaxCyte, will present data on flow electroporation in a podium presentation entitled "Streamlining Antibody Development Using Large Scale, CHO Transient Gene Expression (TGE) followed by Rapid Production of CHO Stable Clones" on Tuesday, May 21, at 1:30 PM within a session dedicated to accelerating cell line and process development.
"Dr. Bradys presentation demonstrates the unmatched performance of the MaxCyte Scalable Transfection Systemsto achieve antibody titers of over 1 gram/liter using transient gene expression in CHO cells. In addition, using the same technology, high yield stable cell lines can be identified within just 6-8 weeks," says Dr. Karen Donato, Executive Vice President of Global Business Development & Marketing at MaxCyte. "From the earliest phases of discovery and development, companies using the MaxCyte transfection platform now have a powerful tool to generate antibodies in CHO cells rapidly and reproducibly in meaningful quantities for identification and characterization."
MaxCyte will also present two scientific posters, both available for viewing throughout the conference. The first poster, entitled "CHO Transient Gene Expression (TGE) Optimization for Multi-Gram Level Antibody Production: Effects of Expression Construct, Post Transfection Cell Density and Feed Conditions" demonstrates a simple, optimized process to achieve antibody titers exceeding 1 gram/liter within 14 days of transfection. This poster is presented in collaboration with Vivalis, a key client and leading provider of innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and recombinant proteins.
The second poster, entitled "Bioproduction Using Large Scale Transient Transfection: From >1.2 grams/L Antibody Titers via Transient Gene Expression (TGE) to Rapid, High Yield Stable Cell Line Generation", presents data demonstrating the utility of the MaxCyte platform at multiple steps in antibody development including high yield antibody production via transient gene expression and rapid generation of stable cell lines in 6-8 weeks for later stage development and biomanufacturing.
"Companies are already realizing the benefits of streamlining progression from early to late stage development by using MaxCytes one-of-a-kind technology that brings together transient gene expression and rapid stable cell generation," says Douglas Doerfler, President, and CEO of MaxCyte. "MaxCyte flow electroporation is a truly enabling technology and we look forward to presenting our latest scientific findings to leaders in the development of biotherapeutics at the 9 th Annual Cell Line Development& Engineering Conference."